- Home
- TFFP vs GLMD Comparison
TFFP vs GLMD Comparison
Compare TFFP & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFFP
- GLMD
- Stock Information
- Founded
- TFFP 2018
- GLMD 2000
- Country
- TFFP United States
- GLMD Israel
- Employees
- TFFP N/A
- GLMD N/A
- Industry
- TFFP Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- TFFP Health Care
- GLMD Health Care
- Exchange
- TFFP Nasdaq
- GLMD Nasdaq
- Market Cap
- TFFP 6.9M
- GLMD 5.9M
- IPO Year
- TFFP 2019
- GLMD 2014
- Fundamental
- Price
- TFFP $0.39
- GLMD $2.93
- Analyst Decision
- TFFP Strong Buy
- GLMD
- Analyst Count
- TFFP 1
- GLMD 0
- Target Price
- TFFP $44.00
- GLMD N/A
- AVG Volume (30 Days)
- TFFP 682.5K
- GLMD 92.9K
- Earning Date
- TFFP 11-26-2024
- GLMD 11-29-2024
- Dividend Yield
- TFFP N/A
- GLMD N/A
- EPS Growth
- TFFP N/A
- GLMD N/A
- EPS
- TFFP N/A
- GLMD N/A
- Revenue
- TFFP $1,202,586.00
- GLMD N/A
- Revenue This Year
- TFFP $60.25
- GLMD N/A
- Revenue Next Year
- TFFP N/A
- GLMD N/A
- P/E Ratio
- TFFP N/A
- GLMD N/A
- Revenue Growth
- TFFP 53.17
- GLMD N/A
- 52 Week Low
- TFFP $0.27
- GLMD $2.73
- 52 Week High
- TFFP $11.00
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- TFFP 23.82
- GLMD 39.04
- Support Level
- TFFP $1.55
- GLMD $2.73
- Resistance Level
- TFFP $3.23
- GLMD $3.13
- Average True Range (ATR)
- TFFP 0.31
- GLMD 0.30
- MACD
- TFFP -0.12
- GLMD 0.02
- Stochastic Oscillator
- TFFP 0.95
- GLMD 16.53
About TFFP TFF Pharmaceuticals Inc.
TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.